{
    "info": {
        "nct_id": "NCT06180278",
        "official_title": "A Long-term, Open-label, Low-interventional Safety Study of Inebilizumab in the Treatment of NMOSD (N-MOmentum LT)",
        "inclusion_criteria": "1. Age 18 years or above, and able to provide written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA] in the United States of America (USA), European Union [EU] Data Privacy Directive in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations.\n2. Have completed at least 2 years in the open-label period of the N-MOmentum study or are newly initiating inebilizumab treatment at a participating site.\n3. Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception as outlined in the protocol (subjects in the Czech Republic only must use 1 additional method of contraception) from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab; cessation of contraception after this point should be discussed with a responsible physician.\n4. Nonsterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide (subjects in the Czech Republic only must use 1 additional method of contraception) from Day 1 for 3 months after receipt of last treatment with inebilizumab.\n5. Sterilized males, without the appropriate post-vasectomy documentation on the absence of sperm in the ejaculate, who are sexually active with a female partner of childbearing potential must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Have any condition that would place the participant at unacceptable risk of complications, interfere with evaluation of inebilizumab or confound the interpretation of participant safety or study results.\n2. Received rituximab or any other B-cell depleting agent after exit from N-MOmentum study, or within the last 12 months prior to screening for non N-MOmentum participants.\n3. Known history of allergy or reaction to any component of inebilizumab formulation or history of anaphylaxis following any biologic therapy\n4. Have a severe clinically significant infection, including active chronic infection such as hepatitis B\n5. Have active or untreated latent tuberculosis\n6. Have a history of progressive multifocal leukoencephalopathy (PML)\n7. Is severely immunocompromised state\n8. Have active malignancies",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Sterilized males, without the appropriate post-vasectomy documentation on the absence of sperm in the ejaculate, who are sexually active with a female partner of childbearing potential must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab.",
                "criterions": [
                    {
                        "exact_snippets": "Sterilized males, without the appropriate post-vasectomy documentation on the absence of sperm in the ejaculate",
                        "criterion": "sterilized male post-vasectomy documentation",
                        "requirement": {
                            "requirement_type": "documentation of absence of sperm in ejaculate",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "sexually active with a female partner of childbearing potential",
                        "criterion": "sexual activity with female partner of childbearing potential",
                        "requirement": {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "sexually active with a female partner of childbearing potential",
                        "criterion": "sexual activity with female partner of childbearing potential",
                        "requirement": {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab",
                        "criterion": "use of condom and spermicide",
                        "requirement": {
                            "requirement_type": "use of condom",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab",
                        "criterion": "use of condom and spermicide",
                        "requirement": {
                            "requirement_type": "use of spermicide",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab",
                        "criterion": "use of condom and spermicide",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Sterilized males, without the appropriate post-vasectomy documentation on the absence of sperm in the ejaculate",
                                        "criterion": "sterilized male post-vasectomy documentation",
                                        "requirement": {
                                            "requirement_type": "documentation of absence of sperm in ejaculate",
                                            "expected_value": false
                                        }
                                    },
                                    {
                                        "exact_snippets": "sexually active with a female partner of childbearing potential",
                                        "criterion": "sexual activity with female partner of childbearing potential",
                                        "requirement": {
                                            "requirement_type": "sexual activity",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "sexually active with a female partner of childbearing potential",
                                        "criterion": "sexual activity with female partner of childbearing potential",
                                        "requirement": {
                                            "requirement_type": "partner childbearing potential",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab",
                                        "criterion": "use of condom and spermicide",
                                        "requirement": {
                                            "requirement_type": "use of condom",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab",
                                        "criterion": "use of condom and spermicide",
                                        "requirement": {
                                            "requirement_type": "use of spermicide",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "must use a condom and spermicide from Day 1 for 3 months after receipt of the last treatment with inebilizumab",
                                        "criterion": "use of condom and spermicide",
                                        "requirement": {
                                            "requirement_type": "duration",
                                            "expected_value": {
                                                "comparisons": [
                                                    {
                                                        "operator": ">=",
                                                        "value": 3,
                                                        "unit": "months"
                                                    }
                                                ]
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Age 18 years or above, and able to provide written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA] in the United States of America (USA), European Union [EU] Data Privacy Directive in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations.",
                "criterions": [
                    {
                        "exact_snippets": "Age 18 years or above",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "able to provide written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "ability to provide",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA] in the United States of America (USA), European Union [EU] Data Privacy Directive in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures",
                        "criterion": "locally required authorization",
                        "requirement": {
                            "requirement_type": "obtained prior to protocol-related procedures",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age 18 years or above",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "able to provide written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "ability to provide",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA] in the United States of America (USA), European Union [EU] Data Privacy Directive in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures",
                        "criterion": "locally required authorization",
                        "requirement": {
                            "requirement_type": "obtained prior to protocol-related procedures",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Have completed at least 2 years in the open-label period of the N-MOmentum study or are newly initiating inebilizumab treatment at a participating site.",
                "criterions": [
                    {
                        "exact_snippets": "Have completed at least 2 years in the open-label period of the N-MOmentum study",
                        "criterion": "participation duration in open-label period of the N-MOmentum study",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "are newly initiating inebilizumab treatment at a participating site",
                        "criterion": "inebilizumab treatment initiation status",
                        "requirement": {
                            "requirement_type": "initiation status",
                            "expected_value": "newly initiating"
                        }
                    },
                    {
                        "exact_snippets": "are newly initiating inebilizumab treatment at a participating site",
                        "criterion": "inebilizumab treatment initiation status",
                        "requirement": {
                            "requirement_type": "site",
                            "expected_value": "participating site"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Have completed at least 2 years in the open-label period of the N-MOmentum study",
                                "criterion": "participation duration in open-label period of the N-MOmentum study",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "are newly initiating inebilizumab treatment at a participating site",
                                "criterion": "inebilizumab treatment initiation status",
                                "requirement": {
                                    "requirement_type": "initiation status",
                                    "expected_value": "newly initiating"
                                }
                            },
                            {
                                "exact_snippets": "are newly initiating inebilizumab treatment at a participating site",
                                "criterion": "inebilizumab treatment initiation status",
                                "requirement": {
                                    "requirement_type": "site",
                                    "expected_value": "participating site"
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "7. Is severely immunocompromised state",
                "criterions": [
                    {
                        "exact_snippets": "Is severely immunocompromised state",
                        "criterion": "immunocompromised state",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Is severely immunocompromised state",
                    "criterion": "immunocompromised state",
                    "requirement": {
                        "requirement_type": "severity",
                        "expected_value": "severe"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Have any condition that would place the participant at unacceptable risk of complications, interfere with evaluation of inebilizumab or confound the interpretation of participant safety or study results.",
                "criterions": [
                    {
                        "exact_snippets": "any condition that would place the participant at unacceptable risk of complications",
                        "criterion": "any condition",
                        "requirement": {
                            "requirement_type": "risk of complications",
                            "expected_value": "unacceptable"
                        }
                    },
                    {
                        "exact_snippets": "any condition that would ... interfere with evaluation of inebilizumab",
                        "criterion": "any condition",
                        "requirement": {
                            "requirement_type": "interference with evaluation of inebilizumab",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any condition that would ... confound the interpretation of participant safety or study results",
                        "criterion": "any condition",
                        "requirement": {
                            "requirement_type": "confounding interpretation of participant safety or study results",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "any condition that would place the participant at unacceptable risk of complications",
                        "criterion": "any condition",
                        "requirement": {
                            "requirement_type": "risk of complications",
                            "expected_value": "unacceptable"
                        }
                    },
                    {
                        "exact_snippets": "any condition that would ... interfere with evaluation of inebilizumab",
                        "criterion": "any condition",
                        "requirement": {
                            "requirement_type": "interference with evaluation of inebilizumab",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any condition that would ... confound the interpretation of participant safety or study results",
                        "criterion": "any condition",
                        "requirement": {
                            "requirement_type": "confounding interpretation of participant safety or study results",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Have active malignancies",
                "criterions": [
                    {
                        "exact_snippets": "Have active malignancies",
                        "criterion": "active malignancies",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Have active malignancies",
                    "criterion": "active malignancies",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Have a history of progressive multifocal leukoencephalopathy (PML)",
                "criterions": [
                    {
                        "exact_snippets": "Have a history of progressive multifocal leukoencephalopathy (PML)",
                        "criterion": "progressive multifocal leukoencephalopathy (PML)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Have a history of progressive multifocal leukoencephalopathy (PML)",
                    "criterion": "progressive multifocal leukoencephalopathy (PML)",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Known history of allergy or reaction to any component of inebilizumab formulation or history of anaphylaxis following any biologic therapy",
                "criterions": [
                    {
                        "exact_snippets": "Known history of allergy or reaction to any component of inebilizumab formulation",
                        "criterion": "allergy or reaction to inebilizumab formulation components",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of anaphylaxis following any biologic therapy",
                        "criterion": "anaphylaxis following biologic therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known history of allergy or reaction to any component of inebilizumab formulation",
                        "criterion": "allergy or reaction to inebilizumab formulation components",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of anaphylaxis following any biologic therapy",
                        "criterion": "anaphylaxis following biologic therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Have a severe clinically significant infection, including active chronic infection such as hepatitis B",
                "criterions": [
                    {
                        "exact_snippets": "severe clinically significant infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    },
                    {
                        "exact_snippets": "severe clinically significant infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "severe clinically significant infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active chronic infection such as hepatitis B",
                        "criterion": "chronic infection (e.g., hepatitis B)",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "active chronic infection such as hepatitis B",
                        "criterion": "chronic infection (e.g., hepatitis B)",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active chronic infection such as hepatitis B",
                        "criterion": "chronic infection (e.g., hepatitis B)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "severe clinically significant infection",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": "severe"
                                }
                            },
                            {
                                "exact_snippets": "severe clinically significant infection",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "clinical_significance",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "severe clinically significant infection",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "active chronic infection such as hepatitis B",
                                "criterion": "chronic infection (e.g., hepatitis B)",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "active chronic infection such as hepatitis B",
                                "criterion": "chronic infection (e.g., hepatitis B)",
                                "requirement": {
                                    "requirement_type": "chronicity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "active chronic infection such as hepatitis B",
                                "criterion": "chronic infection (e.g., hepatitis B)",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Received rituximab or any other B-cell depleting agent after exit from N-MOmentum study, or within the last 12 months prior to screening for non N-MOmentum participants.",
                "criterions": [
                    {
                        "exact_snippets": "Received rituximab or any other B-cell depleting agent after exit from N-MOmentum study",
                        "criterion": "receipt of rituximab or any other B-cell depleting agent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "after exit from N-MOmentum study"
                        }
                    },
                    {
                        "exact_snippets": "Received rituximab or any other B-cell depleting agent ... within the last 12 months prior to screening for non N-MOmentum participants",
                        "criterion": "receipt of rituximab or any other B-cell depleting agent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months prior to screening"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Received rituximab or any other B-cell depleting agent ... within the last 12 months prior to screening for non N-MOmentum participants",
                        "criterion": "receipt of rituximab or any other B-cell depleting agent",
                        "requirement": {
                            "requirement_type": "participant group",
                            "expected_value": "non N-MOmentum participants"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Received rituximab or any other B-cell depleting agent after exit from N-MOmentum study",
                        "criterion": "receipt of rituximab or any other B-cell depleting agent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "after exit from N-MOmentum study"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Received rituximab or any other B-cell depleting agent ... within the last 12 months prior to screening for non N-MOmentum participants",
                                "criterion": "receipt of rituximab or any other B-cell depleting agent",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months prior to screening"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Received rituximab or any other B-cell depleting agent ... within the last 12 months prior to screening for non N-MOmentum participants",
                                "criterion": "receipt of rituximab or any other B-cell depleting agent",
                                "requirement": {
                                    "requirement_type": "participant group",
                                    "expected_value": "non N-MOmentum participants"
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "4. Nonsterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide (subjects in the Czech Republic only must use 1 additional method of contraception) from Day 1 for 3 months after receipt of last treatment with inebilizumab.",
                "criterions": [
                    {
                        "exact_snippets": "Nonsterilized males who are sexually active with a female partner of childbearing potential",
                        "criterion": "male sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Nonsterilized males who are sexually active with a female partner of childbearing potential",
                        "criterion": "sexual activity with female partner of childbearing potential",
                        "requirement": {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Nonsterilized males who are sexually active with a female partner of childbearing potential",
                        "criterion": "sexual activity with female partner of childbearing potential",
                        "requirement": {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must use a male condom plus spermicide (subjects in the Czech Republic only must use 1 additional method of contraception) from Day 1 for 3 months after receipt of last treatment with inebilizumab",
                        "criterion": "contraceptive method use",
                        "requirement": {
                            "requirement_type": "contraceptive methods",
                            "expected_value": [
                                "male condom",
                                "spermicide"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "must use a male condom plus spermicide (subjects in the Czech Republic only must use 1 additional method of contraception) from Day 1 for 3 months after receipt of last treatment with inebilizumab",
                        "criterion": "contraceptive method use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "(subjects in the Czech Republic only must use 1 additional method of contraception)",
                        "criterion": "contraceptive method use (Czech Republic only)",
                        "requirement": {
                            "requirement_type": "additional contraceptive method",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception as outlined in the protocol (subjects in the Czech Republic only must use 1 additional method of contraception) from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab; cessation of contraception after this point should be discussed with a responsible physician.",
                "criterions": [
                    {
                        "exact_snippets": "Females of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Females of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "sexually active with a nonsterilized male partner",
                        "criterion": "sexual activity with nonsterilized male partner",
                        "requirement": {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "sexually active with a nonsterilized male partner",
                        "criterion": "sexual activity with nonsterilized male partner",
                        "requirement": {
                            "requirement_type": "partner sterilization status",
                            "expected_value": "nonsterilized male"
                        }
                    },
                    {
                        "exact_snippets": "must use a highly effective method of contraception as outlined in the protocol",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "subjects in the Czech Republic only must use 1 additional method of contraception",
                        "criterion": "contraception method (Czech Republic only)",
                        "requirement": {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "methods"
                            }
                        }
                    },
                    {
                        "exact_snippets": "subjects in the Czech Republic only must use 1 additional method of contraception",
                        "criterion": "contraception method (Czech Republic only)",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": "Czech Republic"
                        }
                    },
                    {
                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                        "criterion": "contraception duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                        "criterion": "contraception duration",
                        "requirement": {
                            "requirement_type": "start time",
                            "expected_value": "from screening"
                        }
                    },
                    {
                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                        "criterion": "contraception duration",
                        "requirement": {
                            "requirement_type": "end time",
                            "expected_value": "6 months after treatment with inebilizumab"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Females of childbearing potential",
                                "criterion": "sex and reproductive status",
                                "requirement": {
                                    "requirement_type": "sex",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "exact_snippets": "Females of childbearing potential",
                                "criterion": "sex and reproductive status",
                                "requirement": {
                                    "requirement_type": "childbearing potential",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "sexually active with a nonsterilized male partner",
                                "criterion": "sexual activity with nonsterilized male partner",
                                "requirement": {
                                    "requirement_type": "sexual activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "sexually active with a nonsterilized male partner",
                                "criterion": "sexual activity with nonsterilized male partner",
                                "requirement": {
                                    "requirement_type": "partner sterilization status",
                                    "expected_value": "nonsterilized male"
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "must use a highly effective method of contraception as outlined in the protocol",
                                        "criterion": "contraception method",
                                        "requirement": {
                                            "requirement_type": "method effectiveness",
                                            "expected_value": "highly effective"
                                        }
                                    },
                                    {
                                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                                        "criterion": "contraception duration",
                                        "requirement": {
                                            "requirement_type": "duration",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                                        "criterion": "contraception duration",
                                        "requirement": {
                                            "requirement_type": "start time",
                                            "expected_value": "from screening"
                                        }
                                    },
                                    {
                                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                                        "criterion": "contraception duration",
                                        "requirement": {
                                            "requirement_type": "end time",
                                            "expected_value": "6 months after treatment with inebilizumab"
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "contraception method (Czech Republic only)",
                                        "criterion": "contraception method (Czech Republic only)",
                                        "requirement": {
                                            "requirement_type": "location",
                                            "expected_value": "Czech Republic"
                                        }
                                    },
                                    {
                                        "exact_snippets": "contraception method (Czech Republic only)",
                                        "criterion": "contraception method (Czech Republic only)",
                                        "requirement": {
                                            "requirement_type": "number of methods",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 2,
                                                "unit": "methods"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                                        "criterion": "contraception duration",
                                        "requirement": {
                                            "requirement_type": "duration",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 6,
                                                "unit": "months"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                                        "criterion": "contraception duration",
                                        "requirement": {
                                            "requirement_type": "start time",
                                            "expected_value": "from screening"
                                        }
                                    },
                                    {
                                        "exact_snippets": "from screening, and must agree to continue using such precautions for 6 months after treatment with inebilizumab",
                                        "criterion": "contraception duration",
                                        "requirement": {
                                            "requirement_type": "end time",
                                            "expected_value": "6 months after treatment with inebilizumab"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "5. Have active or untreated latent tuberculosis",
                "criterions": [
                    {
                        "exact_snippets": "Have active or untreated latent tuberculosis",
                        "criterion": "tuberculosis",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "untreated latent"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}